Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine

TY - JOUR

T1 - Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine

AU - Vollesen, Anne Luise Haulund

AU - Amin, Faisal Mohammad

AU - Ashina, Messoud

PY - 2018/4

Y1 - 2018/4

N2 - Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine pathophysiology and data implicating PAC1 receptor as a future drug target in migraine. Much remains to be fully elucidated about migraine pathophysiology, but recent attention has focused on signaling molecule PACAP38, a vasodilator able to induce migraine attacks in patients who experience migraine without aura. PACAP38, with marked and sustained effect, dilates extracerebral arteries but not the middle cerebral artery. The selective affinity of PACAP38 to the PAC1 receptor makes this receptor a highly interesting and potential novel target for migraine treatment. Efficacy of antagonism of this receptor should be investigated in randomized clinical trials.

AB - Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine pathophysiology and data implicating PAC1 receptor as a future drug target in migraine. Much remains to be fully elucidated about migraine pathophysiology, but recent attention has focused on signaling molecule PACAP38, a vasodilator able to induce migraine attacks in patients who experience migraine without aura. PACAP38, with marked and sustained effect, dilates extracerebral arteries but not the middle cerebral artery. The selective affinity of PACAP38 to the PAC1 receptor makes this receptor a highly interesting and potential novel target for migraine treatment. Efficacy of antagonism of this receptor should be investigated in randomized clinical trials.

U2 - 10.1007/s13311-017-0596-x

DO - 10.1007/s13311-017-0596-x

M3 - Review

C2 - 29464574

SN - 1933-7213

VL - 15

SP - 371

EP - 376

JO - Neurotherapeutics

JF - Neurotherapeutics

IS - 2

ER -